Programs

Takeda Initiative with Global Fund

The Takeda Initiative is an endowment made by Takeda Pharmaceutical, with an annual value of JPY 100,000,000 (approximately USD 1 million). It is designed to support the Global Fund to Fight AIDS, Tuberculosis and Malaria over the period 2010-2019, primarily for the training of health care workers and strengthening of health care systems in Africa. Controlling the spread of the three major infectious diseases is one of the eight targets set by the United Nations Millennium Development Goals (MDGs).

Tanzanian Training Center for International Health

Skilled human resources are the backbone of any performing healthcare system. Many developing countries, however, face a big shortage of qualified healthcare personnel. The Tanzanian Training Centre for International Health (TTCIH) aims to strengthen the Tanzanian healthcare system through sustainable human resources development.

Technology Transfer & ARV Licensing in Developing Countries

Pharmaceutical companies' preferential pricing of antiretrovirals make effective, safe, high quality HIV/AIDS treatments available to developing countries. In some cases, companies also issue voluntary licenses (VLs) which allow local manufacturers in developing countries to produce and sell generic versions of their products. VLs are not a universal solution to HIV/AIDS but a response to specific circumstances. Local factors encouraging VL use include a severe HIV/AIDS epidemic, adequate health care infrastructure, suitable economic conditions and sufficient manufacturing expertise.

The World Diabetes Foundation

The World Diabetes Foundation, established by Novo Nordisk in 2002, works to achieve equal access to diabetes care in the developing world.

Tibotec Cost Recovery Distribution Program

Johnson & Johnson's Tibotec subsidiary collaborates with major not-for-profit suppliers to donate and sell Tibozole TM Miconazole MAT to treat oral thrush in AIDS patients in Sub-Saharan Africa.

TLR9 Inhibitor for Cerebral Malaria

Eisai Co., Ltd.'s ER-820446 is a selective inhibitor of Toll Like Receptor 9 (TLR9) signaling. TLRs are mediators of innate immunity. In vitro, ER-820446 inhibits CpG oligonucleotide (TLR9 agonist)-mediated induction of transcription factors in TLR9 transfected cells and the production of proinflammatory cytokines in dendritic cells. In a short term in vivo model in mice, administration of ER-820446 prevented a systemic cytokine response to a s.c. challenge with CpG oligonucleotide.

Unamos al Mundo por la Vida

Unamos al Mundo por la Vida recruits and educates beggar children in Caracas, Venezuela.

ViiV Healthcare Access to ARVs

In the Least Developed Countries and sub-Saharan Africa GlaxoSmithKline has offered its HIV/AIDS medicines at not-for-profit (nfp) prices since 2001. ViiV Healthcare will maintain this commitment, and will include the additional products in its portfolio. All of ViiV Healthcare's ARVs are now available at not-for-profit prices to public sector customers and not-for-profit organizations in all Least Developed Countries and all of sub-Saharan Africa - 64 countries in total.

ViiV Healthcare Collaborative Research Program for Resource-Poor Settings

ViiV Healthcare is committed to the development of new molecules that target unmet medical needs in HIV. The treatment of children with HIV/AIDS remains a significant unmet medical need and there is a pressing need for new medicines to tackle problems such as drug resistance, complex treatment regimens, and side effects associated with current treatments.

ViiV Healthcare's Positive Action on HIV/AIDS

Set up in 1992, Positive Action is ViiV Healthcare's international HIV/AIDS education, care and community support program. It works with community organizations to build capacity to counter the ignorance and stigma surrounding HIV and AIDS through outreach, education and advocacy. In 2009, ViiV Healthcare provided more than GBP 1 million, funding projects in 46 countries across Africa, Asia, Latin America and Eastern Europe.

Women and Families Initiative

The HIV Collaborative Fund, a community organization that raises funds to support treatment for people living with HIV/AIDS, and Johnson & Johnson are partnering in a Women and Families initiative, which focuses on HIV/AIDS treatment preparation services for women. These services include advocacy, treatment and adherence education, counseling on stigma and discrimination, skills-building workshops, and direct service delivery in each of the communities served. Thousands of women in communities throughout Sub-Saharan Africa have been reached over the past few years.

Youth Speak-Up! HIV Peer Education

Young people in Indonesia account for 46% of all HIV/AIDS infections. Youth Speak-Up! was initiated by the Indonesian Youth Partnership (IYP), a nationwide network of youth leaders fighting for Adolescent Reproductive Health and Rights. Youth Speak-Up! uses a network of peer educators to raise awareness about HIV/AIDS transmission and prevention. Johnson & Johnson supports Youth Speak-Up! programs in which adolescents from 12 provinces are trained to educate others in their communities, reaching more than 3,000 young people.

Pages